Skip to main content

Friday, Oct. 2, 2015, 57 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $329.66 to $5,418,750.00.

Highlighted Stocks Traded by Insiders:

LifeLock (LOCK) - FREE Research Report

Schneider Hilary, who is President at LifeLock, sold 1,103 shares at $8.73 on Oct. 2, 2015. Following this transaction, the President owned 376,334 shares meaning that the stake was reduced by 0.29% with the 1,103-share transaction.

The shares most recently traded at $9.22, up $0.49, or 5.31% since the insider transaction. Historical insider transactions for LifeLock go as follows:

  • 4-Week # shares sold: 4,105
  • 12-Week # shares sold: 10,722
  • 24-Week # shares sold: 24,902

The average volume for LifeLock has been 3.3 million shares per day over the past 30 days. LifeLock has a market cap of $834.9 million and is part of the technology sector and computer software & services industry. Shares are down 51.49% year-to-date as of the close of trading on Friday.

LifeLock, Inc. provides identity theft protection services for consumers; and consumer risk management services for enterprises in the United States. Currently, there are 4 analysts who rate LifeLock a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LOCK - FREE

TheStreet Quant Ratings

rates LifeLock as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full

LifeLock Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cyberonics (CYBX) - FREE Research Report

Browne Gregory H, who is SR VP Finance & CFO at Cyberonics, sold 2,000 shares at $60.20 on Oct. 2, 2015. Following this transaction, the SR VP Finance & CFO owned 34,003 shares meaning that the stake was reduced by 5.56% with the 2,000-share transaction.

Tremmel Jon T, who is Director at Cyberonics, sold 2,000 shares at $60.29 on Oct. 2, 2015. Following this transaction, the Director owned 7,075 shares meaning that the stake was reduced by 22.04% with the 2,000-share transaction.

Alch Darren, who is VP Genl Counsel Asst Sec at Cyberonics, sold 375 shares at $61.38 on Oct. 2, 2015. Following this transaction, the VP Genl Counsel Asst Sec owned 10,478 shares meaning that the stake was reduced by 3.46% with the 375-share transaction.

The shares most recently traded at $62.35, up $0.97, or 1.56% since the insider transaction. Historical insider transactions for Cyberonics go as follows:

  • 4-Week # shares sold: 6,187
  • 12-Week # shares sold: 24,737
  • 24-Week # shares sold: 46,751

The average volume for Cyberonics has been 328,500 shares per day over the past 30 days. Cyberonics has a market cap of $1.6 billion and is part of the health care sector and health services industry. Shares are up 8.78% year-to-date as of the close of trading on Friday.

Cyberonics, Inc., together with its subsidiaries, designs, develops, markets, and sells medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 28.3. Currently, there are 3 analysts who rate Cyberonics a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYBX - FREE

TheStreet Quant Ratings

rates Cyberonics as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and good cash flow from operations. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Cyberonics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Egalet (EGLT) - FREE Research Report

Radie Robert S, who is President and CEO at Egalet, sold 15,000 shares at $12.27 on Oct. 2, 2015. Following this transaction, the President and CEO owned 303,900 shares meaning that the stake was reduced by 4.7% with the 15,000-share transaction.

Musial Stan, who is Chief Financial Officer at Egalet, sold 8,480 shares at $12.32 on Oct. 2, 2015. Following this transaction, the Chief Financial Officer owned 101,900 shares meaning that the stake was reduced by 7.68% with the 8,480-share transaction.

Strobeck Mark, who is Chief Business Officer at Egalet, sold 5,220 shares at $12.56 on Oct. 2, 2015. Following this transaction, the Chief Business Officer owned 106,680 shares meaning that the stake was reduced by 4.66% with the 5,220-share transaction.

The shares most recently traded at $12.63, up $0.07, or 0.55% since the insider transaction. Historical insider transactions for Egalet go as follows:

  • 4-Week # shares sold: 34,456
  • 12-Week # shares sold: 6,000
  • 24-Week # shares sold: 34,456

The average volume for Egalet has been 136,900 shares per day over the past 30 days. Egalet has a market cap of $309.9 million and is part of the health care sector and drugs industry. Shares are up 122.58% year-to-date as of the close of trading on Friday.

Egalet Corporation, a specialty pharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with acute and chronic pain. Currently, there is 1 analyst who rates Egalet a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EGLT - FREE

TheStreet Quant Ratings

rates Egalet as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally high debt management risk. Get the full

Egalet Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.